Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Doctors say changes to US vaccine recommendations are confusing parents and could harm kids - 2Investigate Business Mastercard Choices for Better Rewards and Rewards
- 3vote in favor of Your #1 kind of climate
- 4Vacuum Cleaners That Are Not difficult To Use For Home
- 5The Specialty of Compromise: Examples from Reality
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- German police 'cleared path for fascists with batons,' protesters say
- Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- Ukraine demands army of 800,000 under peace plan
- 5 Great Crossover Vehicles For Eco-friendliness In 2024
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- 5 Side interests That Work on Psychological wellness
